JP2024535124A - 破傷風毒素に結合する抗体およびその使用 - Google Patents

破傷風毒素に結合する抗体およびその使用 Download PDF

Info

Publication number
JP2024535124A
JP2024535124A JP2024538780A JP2024538780A JP2024535124A JP 2024535124 A JP2024535124 A JP 2024535124A JP 2024538780 A JP2024538780 A JP 2024538780A JP 2024538780 A JP2024538780 A JP 2024538780A JP 2024535124 A JP2024535124 A JP 2024535124A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antigen
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535124A5 (enExample
Inventor
ランツァヴェッキア，アントーニオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Original Assignee
Institute for Research in Biomedicine IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB filed Critical Institute for Research in Biomedicine IRB
Publication of JP2024535124A publication Critical patent/JP2024535124A/ja
Publication of JP2024535124A5 publication Critical patent/JP2024535124A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024538780A 2021-09-07 2022-09-06 破傷風毒素に結合する抗体およびその使用 Pending JP2024535124A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2021/074596 2021-09-07
EP2021074596 2021-09-07
PCT/EP2022/074735 WO2023036774A1 (en) 2021-09-07 2022-09-06 Antibodies binding to tetanus toxin and uses thereof

Publications (2)

Publication Number Publication Date
JP2024535124A true JP2024535124A (ja) 2024-09-26
JP2024535124A5 JP2024535124A5 (enExample) 2025-09-17

Family

ID=77864578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538780A Pending JP2024535124A (ja) 2021-09-07 2022-09-06 破傷風毒素に結合する抗体およびその使用

Country Status (5)

Country Link
US (1) US20250129142A1 (enExample)
EP (1) EP4399226A1 (enExample)
JP (1) JP2024535124A (enExample)
CN (1) CN118139879A (enExample)
WO (1) WO2023036774A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119161471B (zh) * 2024-11-19 2025-04-01 北京科兴中维生物技术有限公司 抗破伤风毒素中和抗体及应用
CN120829503B (zh) * 2025-09-18 2025-12-26 北京科兴中维生物技术有限公司 抗破伤风毒素抗体及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
CN1305904C (zh) * 2003-12-30 2007-03-21 龚小迪 人源的抗破伤风毒素单克隆抗体的制备和应用
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
EP3733699A4 (en) * 2017-12-29 2022-06-08 Zhuhai Trinomab Biotechnology Co., Ltd. FULLY HUMANIZED MONOCLONAL NEUTRALIZING ANTIBODY FOR TETANUS TOXIN AND ITS USE

Also Published As

Publication number Publication date
EP4399226A1 (en) 2024-07-17
WO2023036774A1 (en) 2023-03-16
US20250129142A1 (en) 2025-04-24
CN118139879A (zh) 2024-06-04

Similar Documents

Publication Publication Date Title
CN112239496B (zh) 抗体变体及其用途
US20220380458A1 (en) Binding molecules specific for fcgamma riia and uses thereof
EP2115003B1 (en) Human antibodies to human delta like ligand 4
CN113735967B (zh) 人类IgG1 FC区变体及其用途
US8546539B2 (en) Fc receptor-binding polypeptides with modified effector functions
TW201819413A (zh) Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
BRPI0806340A2 (pt) anticorpos de sp35 e usos dos mesmos
KR102862077B1 (ko) 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
TW201942135A (zh) 抗cd27 抗體、其抗原結合片段及其醫藥用途
TW202035455A (zh) 抗ｏｘ４０抗體、其抗原結合片段及其醫藥用途
JP2021508444A (ja) ＦｃＲｎに対する増大した親和性および少なくとも１つのＦｃフラグメント受容体に対する増大した親和性を有するＦｃフラグメントを伴う変異体
EP3757127A1 (en) Deimmunized antibodies binding to alpha-4 integrin and uses thereof
US20250129142A1 (en) Antibodies binding to tetanus toxin and uses thereof
CN114206921B (zh) 与疟原虫环子孢子蛋白结合的抗体及其用途
TW202346361A (zh) Ｓｉｇｌｅｃ—８結合蛋白及其用途
TWI814094B (zh) 貓抗體變異體
WO2023103788A1 (zh) 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
US20240034772A1 (en) Antibodies binding to f-protein of metapneumovirus and uses thereof
CN110300763A (zh) 用于治疗白癜风的抗人cxcr3抗体
HK40070165A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
CN116848133A (zh) 结合偏肺病毒f蛋白的抗体及其用途
TW202413414A (zh) 抗ｉｌｔ４抗體及其醫藥用途
OA20886A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250908